New Jersey, USA-headquartered Cyclacel Pharmaceuticals (Nasdaq: CYCC) suffered a major blow Thursday, as the company announced its leukemia candidate sapacitabine (CYC682) had failed to reach the primary endpoint in a pivotal trial.
Top-line results show that sapacitabine did not achieve a statistically-significant improvement in overall survival. The company’s share price has fallen by a quarter since the announcement was made.
An improved rate of complete remission, a secondary endpoint, was observed in patients who had discontinued therapy at the time of analysis. Other endpoints and safety data were similar between the arms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze